We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00040040
First Posted: June 18, 2002
Last Update Posted: January 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of California, Los Angeles
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to assess potential interactions between intravenous (IV) methamphetamine and oral bupropion.

Condition Intervention Phase
Amphetamine-Related Disorders Drug: Bupropion Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double
Primary Purpose: Diagnostic
Official Title: Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Psychological effects
  • BP, HR

Estimated Enrollment: 20
Study Start Date: June 2002
Estimated Study Completion Date: September 2003
Detailed Description:
This is a human laboratory clinical pharmacology study to assess potential interactions between IV methamphetamine challenge and treatment with oral sustained-release bupropion.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Please contact site director for more details.

Exclusion Criteria:

Please contact site director for more details.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00040040


Locations
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, Texas
University of Texas Health Science Center
Houston, Texas, United States, 77225
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of California, Los Angeles
Investigators
Principal Investigator: Thomas Newton, M.D. National Institute on Drug Abuse (NIDA)
  More Information

ClinicalTrials.gov Identifier: NCT00040040     History of Changes
Other Study ID Numbers: NIDA-CTO-0010-1
First Submitted: June 18, 2002
First Posted: June 18, 2002
Last Update Posted: January 11, 2017
Last Verified: August 2003

Additional relevant MeSH terms:
Amphetamine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Bupropion
Methamphetamine
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Central Nervous System Stimulants
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors